Cholinergic and glutamatergic systems, alpha-7 nicotinic acetylcholine receptor (α-7nAChR) and N-methyl-D-aspartate (NMDA) receptor are strongly implicated with cognitive impairments in Alzheimer's disease (AD). Donepezil, a frequently used drug in the treatment of AD, is only an acetylcholinesterase inhibitor (AChEI), whereas galantamine is an AChEI and a positive allosteric modulator of the α4β2 and α-7nAChR. Memantine is an NMDA receptor antagonist. Donepezil (Aricept), galantamine (Razadyne), memantine (Namenda), and donepezil-memantine combination (Namzaric) are US Food and Drug Administration (FDA)-approved medications for the treatment of AD. Several randomized controlled trials (RCTs) and meta-analyses have shown that the donepezil-memantine combination was better than either drug alone for cognition in AD. Based on these data and the unique properties of galantamine, several studies were conducted evaluating the efficacy of galantamine-memantine combination in AD.
Characteristics of studies with the galantamine and memantine combination for cognitive impairments in elderly people.
Studies

Age (years)
Mean ± SD Retrospective cohort study (1.5 years follow-up) All received ChEI for 6 months.
Then, memantine 5-20 mg was added for 12 weeks. The average daily dose of donepezil was 7 ± 2.5 mg, memantine was 16.7 ± 5.2 mg (average of 2 groups), and galantamine was 17.8 ± 4.6 mg.
ChEI reduced the MMSE score by 1.7 (P < 0.001), HDS-R by 1.8 (P < 0.05), and FAB by 0.8 (P < 0.05).
After the addition of memantine, the galantamine + memantine group showed significantly better preservation of cognitive function compared to donepezil + memantine in MMSE score at 3 months (21 versus 14, P < 0.05), HDS-R score at 12 months (11 versus, 9, P < 0.05), and FAB score at 3 months (15 versus 9, P < 0.05).
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